Thorac Cancer: Maintenance therapy with apatinib after standard first-line chemotherapy in patients with extensive-stage small cell lung cancer (ED-SCLC) further prolongs survival

The standard first-line treatment for extensive-stage small cell lung cancer (ED-SCLC) is chemotherapy-based regimens
.

Although the response rate to chemotherapy is high, the risk of recurrence is high and the prognosis is poor

The standard first-line treatment for extensive-stage small cell lung cancer (ED-SCLC) is chemotherapy-based regimens

The primary endpoints were overall survival (OS) and progression-free survival (PFS)
.

Secondary endpoints include toxicity and safety

The primary endpoints were overall survival (OS) and progression-free survival (PFS)

From March 2017 to August 2018, a total of 12 patients were included in the study, including 9 males and 3 females, with an average age of 56.

Clinical features

Clinical features

At data cutoff, 10 patients had died during the follow-up period until February 2021
.

Median progression-free survival in patients receiving apatinib maintenance therapy was 3.

At data cutoff, 10 patients had died during the follow-up period until February 2021

PFS and OS

PFS and OS

Of the 12 patients, 2 (16.
7%) had partial responses, 4 (33.
3%) had complete responses, 2 (16.
7%) had stable disease, and 4 (33.
3%) had progressive disease
.

ORR and DCR were 50.

Of the 12 patients, 2 (16.

Two patients required dose reductions due to adverse reactions (AEs)

Adverse reactions

Adverse reactions

In conclusion, studies have shown that maintenance therapy with apatinib after standard first-line chemotherapy in patients with extensive-stage small cell lung cancer (ED-SCLC) can further prolong survival, but the number of specimens is small, and further exploration is needed in the future
.

In conclusion, studies have shown that maintenance therapy with apatinib after standard first-line chemotherapy in patients with extensive-stage small cell lung cancer (ED-SCLC) can further prolong survival, but the number of specimens is small, and further exploration is needed in the future
.

Studies have shown that maintenance therapy with apatinib after standard first-line chemotherapy in patients with extensive-stage small cell lung cancer (ED-SCLC) can further prolong survival, but the number of specimens is small, and further exploration is needed in the future

Original source:

Teng F, Xing P, Yang K, Gao L, Tian Z, Li J.
Apatinib as maintenance therapy following standard first-line chemotherapy in extensive disease small cell lung cancer: A phase II single-arm trial.
Thorac Cancer.
2022 Jan 14 .
doi: 10.
1111/1759-7714.
14298.
Epub ahead of print.
PMID: 35029038.

Teng F, Xing P, Yang K, Gao L, Tian Z, Li J.
Apatinib as maintenance therapy following standard first-line chemotherapy in extensive disease small cell lung cancer: A phase II single-arm trial.
Thorac Cancer.
2022 Jan 14 .
doi: 10.
1111/1759-7714.
14298.
Epub ahead of print.
PMID: 35029038.
Leave a message here